The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment of patients with advanced neurofibromatosis type 2 (NF2) with novel molecularly targeted therapies.
V. Subbiah
No relevant relationships to disclose
J. M. Slopis
No relevant relationships to disclose
D. S. Hong
No relevant relationships to disclose
L. S. Angelo
No relevant relationships to disclose
I. E. McCutcheon
No relevant relationships to disclose
R. Kurzrock
No relevant relationships to disclose